FDA's adcomm votes unanimously in favor of Moderna and Pfizer's Covid-19 vaccines for the youngest children
The FDA’s VRBPAC met Wednesday in a tense meeting to decide the fate of both Pfizer/BioNTech and Moderna’s Covid-19 vaccines for the youngest groups of children, from ages 6 months to 6 years. Ultimately, the committee of 21 outside experts voted unanimously in favor of Moderna’s two-shot vaccine, and Pfizer’s three-shot vaccine (both 21-0).
The experts all expressed support for vaccinating children in this youngest population to better prevent against Covid-related hospitalizations and deaths that have risen in this group during the latest wave of the Omicron variant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.